Fig. 3: HAT1 protein is downregulated in progressed patient-derived melanoma samples following BRAF inhibitor treatment. | Oncogenesis

Fig. 3: HAT1 protein is downregulated in progressed patient-derived melanoma samples following BRAF inhibitor treatment.

From: Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

Fig. 3

a Average AQUA scores for pre-treatment and progressed melanoma samples from patients treated with BRAFi or BRAFi + MEKi. b Representative AQUA immunofluorescence scores and merged images of the indicated matched pre-treatment and progressed melanoma samples, stained for DAPI, S100/HMB45, and HAT1. Data are presented as the mean ± SEM. ***p < 0.001, ****p < 0.0001, calculated using Student’s t test.

Back to article page